NZ509604A - TNF-derived peptides for use in treating oedema - Google Patents

TNF-derived peptides for use in treating oedema

Info

Publication number
NZ509604A
NZ509604A NZ509604A NZ50960499A NZ509604A NZ 509604 A NZ509604 A NZ 509604A NZ 509604 A NZ509604 A NZ 509604A NZ 50960499 A NZ50960499 A NZ 50960499A NZ 509604 A NZ509604 A NZ 509604A
Authority
NZ
New Zealand
Prior art keywords
peptide
tnf
amino acid
oedema
peptide according
Prior art date
Application number
NZ509604A
Other languages
English (en)
Inventor
Rudolf Lucas
Baetselier Patrick De
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Innogenetics N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N filed Critical Innogenetics N
Publication of NZ509604A publication Critical patent/NZ509604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ509604A 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema NZ509604A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (1)

Publication Number Publication Date
NZ509604A true NZ509604A (en) 2003-05-30

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509604A NZ509604A (en) 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema

Country Status (20)

Country Link
US (2) US20030105021A1 (https=)
EP (3) EP1264599B1 (https=)
JP (1) JP4542266B2 (https=)
CN (1) CN1181886C (https=)
AT (2) ATE374039T1 (https=)
AU (1) AU764992B2 (https=)
BR (1) BR9912899A (https=)
CA (1) CA2334941C (https=)
CZ (1) CZ302862B6 (https=)
DE (2) DE69938743D1 (https=)
DK (1) DK1264599T3 (https=)
ES (1) ES2296872T3 (https=)
HU (1) HU227661B1 (https=)
IL (2) IL141064A0 (https=)
NZ (1) NZ509604A (https=)
PL (1) PL203706B1 (https=)
PT (1) PT1264599E (https=)
TR (1) TR200100338T2 (https=)
WO (1) WO2000009149A1 (https=)
ZA (1) ZA200100656B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US10925924B2 (en) 2014-03-18 2021-02-23 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
IL141064A0 (en) 2002-02-10
US20030105021A1 (en) 2003-06-05
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
AU5620999A (en) 2000-03-06
HK1051805A1 (en) 2003-08-22
IL141064A (en) 2009-09-01
ATE395072T1 (de) 2008-05-15
ZA200100656B (en) 2005-06-29
PT1264599E (pt) 2008-01-07
HUP0103117A2 (hu) 2001-12-28
CZ2001538A3 (cs) 2001-08-15
EP1247531A2 (en) 2002-10-09
ES2296872T3 (es) 2008-05-01
EP1247531A3 (en) 2002-12-18
EP1264599A1 (en) 2002-12-11
CA2334941C (en) 2011-08-09
DK1264599T3 (da) 2008-02-04
CA2334941A1 (en) 2000-02-24
ATE374039T1 (de) 2007-10-15
WO2000009149A1 (en) 2000-02-24
DE69937206T2 (de) 2008-06-19
EP1264599B1 (en) 2007-09-26
PL345997A1 (en) 2002-01-14
DE69938743D1 (de) 2008-06-26
DE69937206D1 (de) 2007-11-08
EP1105152A1 (en) 2001-06-13
HU227661B1 (hu) 2011-10-28
AU764992B2 (en) 2003-09-04
US7258861B2 (en) 2007-08-21
JP2002522508A (ja) 2002-07-23
EP1247531B1 (en) 2008-05-14
PL203706B1 (pl) 2009-11-30
CN1181886C (zh) 2004-12-29
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
BR9912899A (pt) 2001-05-08
JP4542266B2 (ja) 2010-09-08
TR200100338T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
CA2334941C (en) Tnf-derived peptides for use in treating oedema
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US8092803B2 (en) VEGF antagonist formulations for intravitreal administration
JPH04504429A (ja) 腫瘍の脈管形成を抑制する方法
US5238919A (en) Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US9555080B2 (en) Medicament for therapeutic treatment and/or improvement of sepsis
NO302527B1 (no) Fremgangsmåte ved fremstilling av polypeptid med antikoagulerende aktivitet
US5792450A (en) Purified human CSF-1
KR20030060988A (ko) 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도
Sugimoto et al. Functional property of von Willebrand factor under flowing blood
HK1051802A (en) Tnf-derived peptides for use in treating oedema
HK1051805B (en) Tnf-derived peptides for use in treating oedema
MXPA01001527A (en) Tnf-derived peptides for use in treating oedema
JP4698973B2 (ja) 毒性が低下したｔｎｆファミリーのリガンド、リガンドのアゴニストの投与方法
WO1996011700A1 (en) Reduction of mammalian neoplasms with phospholipase a2 activatiing substances
KR20100040805A (ko) Ｖｅｇｆ－ｄ 변이체 및 그의 사용
US20110021411A1 (en) Reverse protein
KR20010032511A (ko) 조혈 간세포를 이동시키는 방법

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: DR. RUDOLF LUCAS, BE

Free format text: OLD OWNER(S): INNOGENETICS N.V.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired